VIVA
维亚生物科技控股集团
VIVA BIOTECH HOLDINGS
股票代號:1873

Issue 14
NEWSLETTER
Jan – Apr 2023

VIVA Company News

Viva Biotech Announced 2022 ESG Report

On April 26, 2023, Viva Biotech Holdings (1873.HK) announced 2022 ESG Report. “The Company has been committed to aligning pursuit of business development with fulfilment of its environmental and social responsibilities, and while proactively propelling business growth, the Group has integrated the ESG philosophy into the whole process of business development.

Viva Biotech Announced 2022 Annual Results

On March 30, 2023, Viva Biotech (1873.HK) released its 2022 annual results report. During the year ended December 31, 2022 (the “Reporting Period”), the revenue of the Group increased to RMB2,379.6 million from RMB2,104.1 million for the corresponding period last year, representing a YoY increase of approximately 13.1%. The gross profit increased from RMB651.0 million for the corresponding period last year to RMB815.7 million, representing a YoY increase of approximately 25.3%. The Group recorded an adjusted net loss of RMB133.9 million. This was mainly affected by various factors including the decline in personnel utilization rate due to the resurgence of COVID-19 in mainland China, fair value changes in our portfolio companies as a result of market fluctuations, and to some extent, the cultivation of our early-stage new businesses.

As of Dec 31, 2022, the Company’s revenue from CRO business increased by approximately 20.9% from RMB740.5 million for the corresponding period of last year to RMB895.1 million. The Company’s order backlog amounted to approximately RMB1,050.0 million, representing an increase of approximately 8.8% from RMB965.0 million for the corresponding period of last year. The Group made great efforts to strengthen the strategic integration with Langhua Pharmaceutical. During the Reporting Period, Langhua Pharmaceutical’s revenue amounted to RMB1,484.6 million, representing a year-on-year increase of approximately 8.9%; and its gross profit amounted to RMB418.3 million, representing a year-on-year increase of approximately 35.5%. In addition, Langhua Pharmaceutical plans to build a new production capacity of 400 cubic meters in 2024, and has started the relevant ground construction work. These capacity additions will provide adequate support to our future revenue growth. In respect of EFS, As of December 31, 2022, the Group had invested in a total of 91 portfolio companies. At present, the Group has successfully realized 9 investment exits or partial exits, and may have an additional 11 potential exits for our portfolio companies in the next one to three years. In addition, the Company is proactively applying for a fund manager license in the PRC, and intends to conduct incubation business through the establishment of investment funds in future.

Research & Development Progress

the QY211 Gel of E-nitiate Biopharmaceuticals, A Joint Venture Subsidiary of VivaVision, Has Completed the First Dose Enrollment in Phase Ia Healthy Subjects

In April, E-nitiate Biopharmaceuticals, which was jointly established by VivaVision and Betta Fund, is currently undergoing phase I clinical study aimed to evaluate the safety and preliminary efficacy of topical QY211 gel in Chinese healthy subjects and patients with mild to moderate atopic dermatitis.

Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial

April 18, 2023, Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, were pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial (NCT05802173) of topical TDM-105795 solution.

This clinical trial in the AGA program includes 16 weeks dosing of two different active formulation strengths and placebo in a study entitled, "A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia".

AmacaThera Doses First Subjects in Phase 1 Clinical Trial for AmacaGel™ Therapeutic Platform

TORONTO, March 9, 2023, AmacaThera Inc is a clinical-stage company transforming therapeutics to make a difference in patient health. Recently they announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™. AmacaThera's pipeline development will progress throughout 2023 with AMT-143 Phase 1 efficacy studies in post-operative pain alongside the rapid pre-clinical advancement of AMT-456 for multi-modal treatment of unmet medical needs in oncology.

Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for First Reversible Thrombolytic Agent at ISC 2023

February 9, 2023, Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, today presented positive results of a Phase 1 single ascending dose safety study in healthy volunteers of the company's novel von Willebrand Factor (vWF)-targeting thrombolytic agent, BB-031. BB-031 demonstrated safety and tolerability following a single intravenous dose ranging from 0.1 mg/kg to 4.0 mg/kg and dose-dependent patterns of vWF binding and changes in platelet function.

Research & Development Progress

AceLink Presented Phase I Clinical Data of AL01211 and AL00804 During the 2023 WORLD Symposium

AceLink Therapeutics, Inc. (AceLink) is an innovative biopharmaceutical company developing transformative therapies for genetic diseases. Recently they presented positive data from a Phase 1 trial of AL01211 in healthy volunteers and preclinical data on the development of AL00804, a novel brain penetrant glucosylceramide synthase inhibitor.

AL01211 is a novel, oral, non-brain penetrant glucosylceramide synthase inhibitor (GCSi) being developed for the treatment of Fabry disease. The Phase 1 trial is a randomized, double-blind, placebo-controlled, dose escalation study of AL01211 in 69 healthy adult participants.

AL00804, a highly brain penetrant GCS inhibitor, efficiently reduced GL1 accumulation in the brain of preclinical models . In a head-to-head comparison in a neuronopathic model for Gaucher disease, AL00804 exhibited higher potency and greater brain penetration compared to other GCS inhibitors currently in development. AL00804 is IND-ready and aims to be the best-in-class treatment of neuronopathic Gaucher disease, GM2 and GM1 gangliosidosis.

Technoderma Medicines Initiates TDM-180935 Atopic Dermatitis Clinical Program with Phase 1 Dose Escalation Trial

Feb. 9, 2023, Technoderma Medicines, Inc. ("the Company") is a clinical stage biopharmaceutical company. They were pleased to report the Company has begun dosing healthy volunteer subjects in its Phase 1 clinical trial of topical TDM-180935 ointment.

This first clinical trial in the Atopic Dermatitis (AD) program includes single dose and multidose escalation cohorts in a study entitled, "A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-180935 Following Topical Administration in Healthy Male Subjects". Study objectives are to evaluate the safety and pharmacokinetics of topical TDM-180935. One U.S. clinical site is currently participating in this study under an open IND with FDA.

QureBio Q-1801 Project was approved by CDE

QureBio announced that its independently developed Q-1801 project received the domestic CDE clinical trial approval notice on January 11, 2023. Previously, the project had received the FDA clinical approval. Q-1801 was developed by QureBio using its antibody engineering technology platform, which is the world's first bispecific antibody simultaneous targeting SIRPα And PD-L1. Q-1801 is also the second clinical application project of QureBio. So far, QureBio has obtained four IND approvals from China and United States.

Research & Development Progress

Arthrosi Announces Positive Topline Results for AR882 Phase 2b Study

SAN DIEGO, Jan. 5, 2023, Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, announced positive topline results from its Phase 2b clinical study of AR882 for the treatment of chronic gout, providing a strong foundation to advance into Phase 3 clinical development.

AmacaThera's Lung Cancer Applications Recognized in QuickFire Challenge

TORONTO, Jan. 4, 2023 - AmacaThera is a clinical-stage biotechnology company developing advanced injectable biomaterials for local, sustained delivery of oncology and pain therapeutics. Recently they have received grant funding from the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma.

Business Progress

Genhouse Bio was listed on the "2022 Healthcare Venture 50 in the Investment Industry"

Suzhou, China, January 12, 2023——Genhouse Bio is dedicated to transforming cancer treatment with next-generation small-molecule therapeutics by utilizing integrating technology platform. Recently, they has been ranked in the "2022 Healthcare Venture 50 in the Investment Industry", which is a recognition of Genhouse's continuous innovation capability and R&D strength.

In 2022, Genhouse Bio completed several hundred million RMB Series B financing, and built and improved four new drug R&D centers: Innovation Research Center, Drug Design and Discovery Center, New Drug Screening and Evaluation Center, and Clinical Development Center. The company's core products, GH35, a KRAS G12C inhibitor, and GH21, a SHP2 inhibitor, are rapidly advancing in clinical trials. Recently, GH55, an ERK inhibitor, has successfully obtained the clinical approval in the United States, and completed the first patient dosing in Phase I clinical trial in China. Meanwhile, the more internationally valuable and innovative “Pipeline 2.0” project has also made significant breakthroughs, with several projects expected to file clinical trial applications in 2023.

Business Progress

AIxplorerBio Relocated its New Headquarters and Signed a Cooperation Agreement with Xiuzhou District

January 12, 2023, AIxplorerBio held new headquarters' relocation ceremony in Xiuzhou district, Jiaxing. More than 20 guests, including Mr. Yifeng Wang, the member of Standing Committee of the CPC Xiuzhou District Committee and Secretary of the CPC Working Committee of Xiuzhou High Tech Zone, Prof. Bing Su, Professor of Shanghai Jiao Tong University School of Medicine and Director of Shanghai Institute of Immunology, Prof. Yu Tang, Doctoral Supervisor of East China University of Science and Technology, the management team of AIxplorerBio, partners, scientists and investment institutions in various biomedical fields, attended the ceremony and celebrated this milestone together.

In addition, on December 15, 2022, AIxplorerBio and Xiuzhou National High-tech Zone formally signed a cooperation agreement to help the company enter a new stage of development. On the one hand, the signing of this contract has implemented the planned site selection of the office space and biological laboratory of AIxplorerBio in Jiaxing. On the other hand, they will also cooperate to promote open technologies and multi-dimensional products, quickly and high-quality discover and develop innovative drugs in the fields of autoimmune and neurodegenerative diseases, and give full play to the advantages of the integration of drug research and development and AI.

VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases

TEL AVIV, Israel and SHANGHAI—VivaVision is a pharmaceutical company developing innovative therapies for ocular diseases. Recently, they announced that they are partnering with Everads Therapy, a biotech company developing optimized retinal therapies using its novel suprachoroidal drug delivery technology in order to develop safer, more effective, and more durable treatments for retinal diseases.

The two companies will develop certain undisclosed molecules of VivaVision for suprachoroidal delivery using Everads' technology and expertise. The molecules selected are potent small molecules that work against well-validated therapeutic targets in retinal disease management, and that are designed to enable extended durability in the suprachoroidal space.

Under the terms of collaboration agreement, the companies will jointly conduct pre-clinical research activities, in order to identify lead candidates for future clinical development and commercialization.

Business Progress

Triumvira Immunologics Establishes Collaboration with Merck to Evaluate TAC01-HER2 Cell Therapy in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2-positive Solid Tumors

AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Jan. 5, 2023 -- Triumvira Immunologics is a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. Today they announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the U.S. and Canada). Triumvira's ongoing TACTIC-2 trial will evaluate the use of its novel autologous cell therapy TAC01-HER2 as a monotherapy but also in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the treatment of HER2-positive solid tumors.

At the European Society for Medical Oncology 2022 Congress, Triumvira presented interim data from the ongoing TACTIC-2 Phase 1/2 trial that demonstrated the safety and preliminary efficacy of TAC01-HER2 in patients with HER2-positive solid tumors regardless of level of expression. TACTIC-2 is actively enrolling participants at five clinical trial sites across the U.S. and Canada. The expansion phase of the trial is expected to launch in 2023. The trial will enroll a monotherapy arm with TAC01-HER2 and a combination therapy arm with TAC01-HER2 and KEYTRUDA, in patients with HER2-positive solid tumors.

Merck will supply Triumvira with KEYTRUDA for the trial and the two companies will form a Joint Development Committee to review the clinical trial results.

Investment Progress

Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies

CAMBRIDGE, Mass., March 15, 2023-- Mediar Therapeutics Inc., is a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis. Recently they announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli Lilly & Company, Ono Venture Investment and Mass General Brigham Ventures. Viva also continued to invest in this round.

Mediar's portfolio comprises three novel targets that are readily detectible in blood and correlate to disease severity, enabling a de-risked approach to clinical development. The series A financing will support advancement of the company's portfolio of first-in-class antibody treatments, which offer unique potential to address fibrosis at varying stages of the disease, with two programs advancing into human studies in 2024.

Investment Progress

QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases

CAMBRIDGE, Mass., March 9, 2023 – QurAlis Corporation is a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets. Recently they announced it has closed an oversubscribed $88 million Series B financing, bringing the total funds raised to $143.5 million. The financing was led by EQT Life Sciences, investing from the LSP Dementia Fund, Sanofi Ventures, and Droia Ventures, with participation from the ALS Investment Fund and existing investors LS Polaris Innovation Fund, Mission BioCapital, INKEF Capital, Dementia Discovery Fund, Amgen Ventures, MP Healthcare Venture Management, Mitsui Global Investment, Dolby Family Ventures, Mission Bay Capital, and Sanford Biosciences.

The proceeds from the financing will fund clinical development of QRL-201 and QRL-101, the Company's lead product candidates in ALS. In addition, the financing will support ongoing and planned research, as well as the advancement of QurAlis' pipeline with therapeutic candidates that target specific components of ALS and genetically related frontotemporal dementia (FTD) pathology and defined ALS patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.

TechnoDerma Completed the Series A+ Funding of Tens of Millions of RMB

On January 13, TechnoDerma Medicines Inc. (hereinafter referred to as "TechnoDerma") is an innovation-oriented R&D biotech company focusing on the development of novel small molecule drugs for dermatological diseases. Recently TechnoDerma announced that they have completed the Series A+ funding of tens of millions of RMB. Thanks to the capital market's high recognition of TechnoDerma's Androgenetic Alopecia (AGA) and Atopic Dermatitis (AD) clinical assets, the company has received the support from the Chengdu Biological City No.1 Equity Investment Fund Partnership (L.P.) and Chengdu Hi Tech Investment Development in this round of financing.

According to Dr. Wang, in the future, TechnoDerma will continue developing novel therapeutics for the treatment of AGA, AD, psoriasis, SLE, scar and other skin diseases. After the AGA and AD projects have entered the Phase I clinical trial, the company will further promote its external medicine for the treatment of psoriasis to enter the Phase 1 study in 2023. "The company will seek cooperation with excellent industrial partners in an open and active cooperation mode to promote the company's clinical development, industrialization and commercialization."

About Viva Biotech

Listing Date
2019.05.09
Price (2023.05.23)
HKD 1.36
52 WK Range
HKD 1.16-3.11
Market Cap (2023.05.23)
HKD 2.632B

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage structure-based drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX, CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of December 31, 2022, Viva Biotech has provided drug R&D and production services to 2,076 biotech and pharmaceutical clients around the world. We have invested and incubated 91 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers, improve R&D and production level, and the service capacity, so as to provide high-quality and diversified services for more drug discovery start-ups, as well as the medium and large pharmaceutical enterprises around the world. We hope to benefit more patients through Viva's platform.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com
For further information, please contact: Tel: 852-3150 6788
Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com